vs
Side-by-side financial comparison of Magnera Corp (MAGN) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $792.0M, roughly 1.9× Magnera Corp). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs -4.3%, a 8.7% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs 12.8%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $-13.0M). Over the past eight quarters, Magnera Corp's revenue compounded faster (54.9% CAGR vs 41.2%).
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
MAGN vs ONC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $792.0M | $1.5B |
| Net Profit | $-34.0M | $66.5M |
| Gross Margin | 12.2% | 90.5% |
| Operating Margin | 1.8% | 12.4% |
| Net Margin | -4.3% | 4.4% |
| Revenue YoY | 12.8% | 32.8% |
| Net Profit YoY | 43.3% | 143.8% |
| EPS (diluted) | $-0.95 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $792.0M | $1.5B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | $839.0M | $1.3B | ||
| Q1 25 | $824.0M | $1.1B | ||
| Q4 24 | $702.0M | $1.1B | ||
| Q3 24 | $332.1M | $1.0B | ||
| Q2 24 | $556.0M | $929.2M | ||
| Q1 24 | $558.0M | $751.7M |
| Q4 25 | $-34.0M | $66.5M | ||
| Q3 25 | — | $124.8M | ||
| Q2 25 | $-18.0M | $94.3M | ||
| Q1 25 | $-41.0M | $1.3M | ||
| Q4 24 | $-60.0M | $-151.9M | ||
| Q3 24 | $-15.2M | $-121.3M | ||
| Q2 24 | $19.0M | $-120.4M | ||
| Q1 24 | $14.0M | $-251.2M |
| Q4 25 | 12.2% | 90.5% | ||
| Q3 25 | — | 86.1% | ||
| Q2 25 | 10.7% | 87.5% | ||
| Q1 25 | 10.7% | 85.2% | ||
| Q4 24 | 10.1% | 85.8% | ||
| Q3 24 | 10.7% | 83.0% | ||
| Q2 24 | 6.6% | 85.1% | ||
| Q1 24 | 6.2% | 83.4% |
| Q4 25 | 1.8% | 12.4% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | 1.5% | 6.7% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | -3.1% | -7.0% | ||
| Q3 24 | 0.9% | -12.0% | ||
| Q2 24 | 3.1% | -11.5% | ||
| Q1 24 | 3.8% | -34.8% |
| Q4 25 | -4.3% | 4.4% | ||
| Q3 25 | — | 8.8% | ||
| Q2 25 | -2.1% | 7.2% | ||
| Q1 25 | -5.0% | 0.1% | ||
| Q4 24 | -8.5% | -13.5% | ||
| Q3 24 | -4.6% | -12.1% | ||
| Q2 24 | 3.4% | -13.0% | ||
| Q1 24 | 2.5% | -33.4% |
| Q4 25 | $-0.95 | $0.05 | ||
| Q3 25 | — | $0.08 | ||
| Q2 25 | $-0.51 | $0.06 | ||
| Q1 25 | $-1.15 | $0.00 | ||
| Q4 24 | $-1.69 | $-0.10 | ||
| Q3 24 | $-0.33 | $-0.09 | ||
| Q2 24 | $0.60 | $-0.09 | ||
| Q1 24 | $0.44 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $264.0M | $4.5B |
| Total DebtLower is stronger | $1.9B | $836.4M |
| Stockholders' EquityBook value | $1.0B | $4.4B |
| Total Assets | $3.9B | $8.2B |
| Debt / EquityLower = less leverage | 1.86× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $264.0M | $4.5B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | $276.0M | $2.8B | ||
| Q1 25 | $282.0M | $2.5B | ||
| Q4 24 | $215.0M | $2.6B | ||
| Q3 24 | $230.0M | $2.7B | ||
| Q2 24 | $33.9M | $2.6B | ||
| Q1 24 | $30.2M | $2.8B |
| Q4 25 | $1.9B | $836.4M | ||
| Q3 25 | — | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $877.4M | — | ||
| Q1 24 | $884.7M | — |
| Q4 25 | $1.0B | $4.4B | ||
| Q3 25 | — | $4.1B | ||
| Q2 25 | $1.1B | $3.8B | ||
| Q1 25 | $1.1B | $3.5B | ||
| Q4 24 | $1.1B | $3.3B | ||
| Q3 24 | $2.1B | $3.4B | ||
| Q2 24 | $2.4B | $3.4B | ||
| Q1 24 | $2.4B | $3.4B |
| Q4 25 | $3.9B | $8.2B | ||
| Q3 25 | — | $7.6B | ||
| Q2 25 | $4.1B | $6.3B | ||
| Q1 25 | $4.1B | $5.8B | ||
| Q4 24 | $4.0B | $5.9B | ||
| Q3 24 | $2.8B | $5.8B | ||
| Q2 24 | $1.5B | $5.7B | ||
| Q1 24 | $1.5B | $5.7B |
| Q4 25 | 1.86× | 0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.77× | — | ||
| Q1 25 | 1.83× | — | ||
| Q4 24 | 1.80× | — | ||
| Q3 24 | 0.91× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $417.3M |
| Free Cash FlowOCF − Capex | $-13.0M | $379.8M |
| FCF MarginFCF / Revenue | -1.6% | 25.4% |
| Capex IntensityCapex / Revenue | 1.9% | 2.5% |
| Cash ConversionOCF / Net Profit | — | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $417.3M | ||
| Q3 25 | — | $402.6M | ||
| Q2 25 | $0 | $263.6M | ||
| Q1 25 | $65.0M | $44.1M | ||
| Q4 24 | $-58.0M | $75.2M | ||
| Q3 24 | $12.2M | $188.4M | ||
| Q2 24 | $38.0M | $-95.6M | ||
| Q1 24 | $20.0M | $-308.6M |
| Q4 25 | $-13.0M | $379.8M | ||
| Q3 25 | — | $354.5M | ||
| Q2 25 | — | $219.8M | ||
| Q1 25 | $42.0M | $-12.3M | ||
| Q4 24 | $-74.0M | $-17.3M | ||
| Q3 24 | $3.6M | $54.7M | ||
| Q2 24 | $23.0M | $-205.5M | ||
| Q1 24 | $12.5M | $-465.1M |
| Q4 25 | -1.6% | 25.4% | ||
| Q3 25 | — | 25.1% | ||
| Q2 25 | — | 16.7% | ||
| Q1 25 | 5.1% | -1.1% | ||
| Q4 24 | -10.5% | -1.5% | ||
| Q3 24 | 1.1% | 5.5% | ||
| Q2 24 | 4.1% | -22.1% | ||
| Q1 24 | 2.2% | -61.9% |
| Q4 25 | 1.9% | 2.5% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | 1.5% | 3.3% | ||
| Q1 25 | 2.8% | 5.0% | ||
| Q4 24 | 2.3% | 8.2% | ||
| Q3 24 | 2.6% | 13.3% | ||
| Q2 24 | 2.7% | 11.8% | ||
| Q1 24 | 1.3% | 20.8% |
| Q4 25 | — | 6.28× | ||
| Q3 25 | — | 3.22× | ||
| Q2 25 | — | 2.79× | ||
| Q1 25 | — | 34.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.00× | — | ||
| Q1 24 | 1.43× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MAGN
| Other | $451.0M | 57% |
| United States And Canada | $341.0M | 43% |
ONC
Segment breakdown not available.
